Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Our Technology
 

theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery management team


melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsy   Andrew G. Reaume, Ph.D., MBA
   President and CEO, Co-Founder

   Dr. Reaume has been responsible for building a robust, proprietary, clinical
   candidate pipeline for Melior while simultaneously attracting the partnership
   of many of the leading global pharmaceutical companies through Melior’s
   capabilities with in vivo profiling.


Dr. Reaume was previously a Senior Business Analyst at Pfizer, Inc. in the department of genomics and proteomic sciences.  While at Pfizer, he conceived of the idea to create a platform for comprehensively characterizing (phenotyping) genetically modified mice.  He subsequently spearheaded the initiative to build it with a third party collaborator by working closely with scientists throughout the global Pfizer organization, business development professionals, information technology specialists as well as the scientists and business development professionals at the partner company.

 

From 1993 to 1999 Dr. Reaume worked in R&D at Cephalon where he was principally involved in creating animal models of neurodegenerative disease.  In addition to Dr. Reaume’s research activities, at Cephalon he identified and helped coordinate in-licensing opportunities. 

 

In 2003, he received his MBA from the Wharton School where he graduated with honors in Entrepreneurial Management.  He received his PhD in genetics from the University of Connecticut in 1990.

 

melior 

 

                                                melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE             
   Patty Ferrante

  Chief Operating Officer

   Patty has a leadership role in many aspects of Melior's day-to-day operations
   including the implementation, reporting, and oversight of the company's
   financials. She also manages human resources, client services, and
   information technology.
  
   Prior to joining Melior in 2007, Patty held leadership roles in the transportation
   industry with prominent local agents for United Van Lines and Mayflower Transit.

 

She comes to Melior with over 20 years of experience in project management, finance, customer services, and sales management.  Patty received her Bachelor of Arts degree in Management Marketing from Holy Family University in Philadelphia, PA.  When not working, she enjoys spending time with her family, gardening and the beach.

 

 

melior

           

 melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton penns   Ramana Kuchibhatla, Ph.D.
   Senior VP of Clinical Development & Biostatistics

   Dr. Ramana Kuchibhatla received a B.Sc. {Hons} in Mathematics and a M.Sc.
   in Applied Statistics from the Osmania University in Hyderabad, India.  He
   worked at ICMR’s Institute for Research in Medical Statistics in Madras in
   public health and health statistics before joining the Administrative Staff
   College of India in Hyderabad as a Faculty Member in the Center for Energy,
   Environment & Technology. 

He joined the University of Iowa Graduate Program in Geography to major inQuantitative Methods and Environmental Studies.  He received his M.A. and Ph.D. from the University of Iowa, Iowa City, IA, USA.  Subsequently, he worked at ManTech Environmental Technology, Inc. a private consulting company specializing in environmental and health assessments where he studied cancer risks of agricultural chemicals. 

 

His pharmaceutical career spans nearly 20 years starting with Glaxo Wellcome (now GlaxoSmithKline) where he consulted in Biostatistics and later in Clinical Research and Development in the Neurology & Psychiatry therapeutic area.  During his tenure, he was involved in the successful filing of two sNDAs that brought Zyban® and Lamictal® (pediatric indication) to market.  In 2001, he joined Targacept, Inc. as Sr. Director of Clinical Research and Development to help setup Clinical Development, Biostatistics and Data Management functions at Targacept Inc.  Dr. Kuchibhatla helped file several INDs for various neuropsychiatric indications as well as bring several NCEs into clinical development with trials conducted in North America, UK, Eastern Europe, and India.  He was closely involved in several successful in-licensing and out-licensing deals Targacept and played a critical role in their successful IPO in June 2006.

 

In April 2007, Dr. Kuchibhatla left Targacept and founded QED Pharmaceutical Services with offices in North Carolina, USA and in Hyderabad, India to offer integrated clinical research consulting services to the pharmaceutical companies. He helped several companies plan and implement clinical development and regulatory activities in USA, Europe (both Eastern and western), and India over the past 9 years.



melior


melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE   John R. Ciallella, Ph.D.
   Director of Research Operations

  

   Dr. Ciallella is Director of Research Operations and is responsible for

   managing  multiple research projects as well as the overall operation of the 
   facility.  With 13 years experience in the Pharmaceutical industry, Dr. Ciallella  
   has acquired significant expertise in preclinical drug discovery and development,

   mainly in CNS and inflammation.  Dr. Ciallella believes that optimized in vivo
   models should be an important screening component for drug development,  

   specifically for drug repositioning.  

 

As a certified Lean Champion, Dr. Ciallella has worked to develop methods and procedures to optimize efficiencies in research environments and to develop highly integrated and productive research teams.  

Previously Dr. Ciallella was a Senior Research Scientist at Centocor, Inc., a Johnson & Johnson company. Here he was responsible for discovering and assessing neuroprotective biopharmaceuticals, was a member of the CNS Delivery Team, and an integral part of the Molecular Imaging Initiative.  Prior to joining Centocor, Dr. Ciallella was a Research Scientist at Cephalon, Inc., where he led the in vivo screening efforts to identify novel kinase inhibitors for the treatment of Alzheimer’s disease. 

Dr. Ciallella received his Ph.D. from the University of Kentucky Sanders Brown Center on Aging and Department of Microbiology and Immunology.  His postdoctoral training was at the University of Pittsburgh in the lab of Dr. Steven DeKosky, where he studied the biochemical links between traumatic brain injury and Alzheimer’s disease.  Dr. Ciallella has published over 20 peer-reviewed articles, has received grant funding from numerous private and public sources, is a reviewer for several journals, and is a founding member of the International Brain Barriers Society.  Dr. Ciallella enjoys mentoring students and young scientists, and when not working attempts to improve his neglected golf game. 

Dr. Ciallella is the key contact for discussing drug development projects in inflammation and neurological disorders (Alzheimer’s, Parkinson’s, MS).

 


melior

                                                    melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE             
   John A. Gruner, Ph.D.

   Director of Neurophysiology

   Dr. Gruner directs all neurophysiology studies at Melior.  He specializes in
   working with clients to custom-design experiments to evaluate therapeutic
   efficacy in models of motoneuron disease (e.g. G93A transgenic SOD mice),
   neurotrauma, pain and muscle relaxation (nociceptive and proprioceptive spinal
   reflexes and neuromuscular function), sleep / wake and general cortical function
   (including high-frequency EEG analysis and evoked potentials), and EEG-based
pro- and anti-convulsant evaluation. 

During his 19 years at Cephalon, Inc., he designed and supervised neurophysiological and pharmacological studies involving numerous disease areas, including evaluation of neuroprotection by trophic agents, free radical inhibitors, kinase inhibitors, and other compounds in neuropathy, neurodegeneration, and motor neuron disease models.  He has also elucidated mechanisms of action of proprietary analgesic agents and utilized evoked potentials for evaluating functional impairment in models of cognitive disorders such as schizophrenia.  He built and ran Cephalon’s preclinical sleep research laboratory, and studied the actions of dopaminergic agents and other drugs in sleep / wake and convulsant activity. He was a discovery team member for several sleep and wake enhancing and psychostimulant agents, including an H3-receptor inverse agonist (irdabisant) currently in clinical development.

Dr. Gruner received his B.A. from UCSD and Ph.D. at Purdue Univ., where he investigated the role of the cerebellum in motor control. As a postdoctoral fellow and later Research Asst. Professor in the Dept. of Neurosurgery at NYU, he designed stimulation systems for paralyzed muscle, was involved in experiments elucidating the role of synapsin phosphorylation in synaptic vesicle release, and carried out electrophysiological and behavioral studies to evaluate treatment efficacy using the spinal cord injury model he helped develop at NYU.  Dr. Gruner is author / co-author on over 40 publications and 1 patent in various areas of neurophysiology.  

melior

                                                    melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE             

   Amy DiCamillo

   Director of Scientific Operations

   Amy DiCamillo is Director of Scientific Operations and is responsible for
   managing multiple research projects.  Amy has 19 years experience in the
   Pharmaceutical industry,  and has acquired considerable expertise in preclinical
   drug discovery and development, mainly in CNS behavioral models.  Amy
   passionately strives for excellence and believes that attention to detail is a critical
   component for producing quality data.  She has worked  to develop, validate, and
   optimize behavior assays for the drug discovery environment  under these
   guiding principles.

Prior to joining Melior Discovery, Amy was a Research Scientist at Cephalon, Inc., where she worked in CNS biology developing in vivo animal models for cognition, anxiety/depression, locomotor activity, and pain.  Amy received her M.S. from the West Chester University of PA where she studied the locomotor effects of Modafinil in MPTP mice while working full-time at Cephalon.  During her 19 years in drug discovery, Amy has authored or coauthored over 20 peer reviewed articles or scientific meeting presentations.  Amy enjoys developing new animal behavior models and troubleshooting the challenges that are often posed in the process.  When not working she also enjoys spending time with her family and releasing energy through zumba and step aerobics classes.

Amy DiCamillo is the key contact for discussing in vivo behavioral models.


melior

                       melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE                      
  
Angela Batman, Ph.D., GDL
   Director of Behavioral Pharmacology

   Dr. Batman has 13 years experience in CNS pharmacology, in particular the use
   of preclinical animal models for abuse liability assessment. She worked initially
   in the academic setting at Virginia Commonwealth University’s Institute for Drug
   and Alcohol Studies in conjunction with the Pharmacology and Toxicology
   department where she completed her both her MSc and PhD degrees. During
   this time she studied serotonergic effects of nicotine in mice and rats as well as
   cocaine-like behavioral activity of novel and selective DAT inhibitors using a
   variety of animal models of abuse potential.

 

After completing her doctoral work Dr. Batman worked for 18 months as a senior scientist with Pfizer (Sandwich, England) in their safety pharmacology department. There she completed studies using animal models as tools for determining the abuse potential of new compounds while gaining expertise in both GLP/GMP standards and industry approaches to compound R&D.   During her experience in industry product development she became intrigued by the application of patents for these new compounds and sought to learn the process.  Dr. Batman studied law and obtained a Graduate Diploma in Law from The College of Law in London, UK in 2012.

             

Dr. Batman then returned to the US as a postdoc at the Medical College of Virginia, Virginia Commonwealth University, department of Pharmacology and Toxicology where she investigated the role of GSK3b in ethanol consumption in multiple mouse and rat models.  Dr. Batman has published numerous peer-reviewed articles and has presented at national and international scientific meetings.

 

When she is not in the lab she enjoys training for and has run 19 marathons.

 

 

melior        

                        melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE                       
  Weina Cong, PhD
  Director of Cardiovascular & Metabolic Disease

  Dr. Cong has 12 years experience in metabolic diseases including diabetes,
  obesity, fatty liver disease, and NASH.  She has authored\co-authored over 20
  peer-reviewed articles.

 

  Dr. Cong received her Ph.D. in pharmacology from the Peking Union Medical
  College, China.  During this time, she focused on preclinical pharmacology
studies for metabolic disorders and gained extensive experience on various animal models of metabolic diseases. Subsequently, she conducted her postdoctoral training at the Hospital for Sick Children in Canada during which she investigated the mechanisms of hyperlipidemia.   From 2010 through 2015, as a research fellow, Dr. Cong continued her research experience on metabolic diseases at the Metabolism Unit of National Institute on Aging, USA.  During this time, Dr. Cong also did extensive studies on metabolic alterations in neurodegenerative diseases including Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Discovering endocrine-modulating compounds for metabolic dysfunctions in neurodegeneration was also one of her specialties.  

 

Recently, Dr. Cong joined Melior Discovery.  She truly believes in our mission and drug repositioning strategy and wants to achieve excellence in preclinical pharmacology of drug discovery at Melior Discovery.  In addition to work, Dr. Cong enjoys cooking and nature.

 

 

melior                       

                        melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE                       
 Erin Davis
 Director of Lab Operations

Erin has been with Melior Discovery since 2008.  She came to Melior with several years of experience in both preclinical and clinical fields of research.  She has 10+ years of experience in the field of pharmaceutical research encompassing Pain and Inflammation, Cardiovascular, Gastrointestinal and Neurodegenerative diseases.  Erin has helped developed animal models for pre-clinical testing and has broad experience with in vivo assays, analysis of data, interpretation of results, and presenting information to peers and management.

 

 

melior        

            

            melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE                       
  Ranjana Singh, PhD
 Marketing Associate

 Dr. Singh has 11+ years of experience working on challenging projects in both
  academic and pharmaceutical fields of research. After completing Masters research
  in  India, Dr. Singh moved to the United States in year 2006 for her doctoral education.
  Dr. Singh earned her PhD in Neuroscience from the University of Kentucky, during
  which she characterized role of Calcium activated protein (Calpain 5, a key protein
 involved in neurodegeneration) at the cellular and molecular level in the Central Nervous System. She also examined the role of Calpain 1 and 5 in traumatic brain and spinal cord rodent injury models by evaluating neuronal loss and functional recovery. Overall during her PhD, Dr. Singh got expertise in cellular and molecular neurobiology, cell/tissue culture, microscopy
and animal disease models.

After the completion of her PhD, Dr. Singh worked as a scientific account manager at Absorption Systems in Exton, PA. She was primarily involved in project management, designing preclinical drug development ADMET studies and providing scientific consultancy to American and European pharmaceutical clientele. This experience completed her academic scientific expertise with the knowledge of pharmaceutical business and research operations.

Upon joining Melior Discovery, Dr. Singh has been core member for managing several client studies as well as Melior’s internal projects. She truly believes in the mission and science we perform at Melior Discovery. She wants to achieve excellence in developing disease models and drug discovery at Melior. Other than work, Dr. Singh enjoys yoga, travelling & watching TV with her husband, and spending time with her daughter.

 

               

 

 

Back to top of page